Dear Diary, Janet Yellen made headlines yesterday. She promised the Fed would be “patient” in raising interest rates. Investors must not have known what she meant. With the Dow tearing more than 421 points – or 2.4% – higher, half of investors must have thought she meant higher rates later than expected. The other half…
Shares of the athletic apparel, footwear and accessories retailer, Nike, Inc. (NKE- Analyst Report), slipped 2.9% in yesterday’s after-hours trading session after the company posted second-quarter fiscal 2015 results. Various analysts blamed soft future orders for the fall in share price. Nike’s global future orders, slated for delivery from Dec 2014 through Apr 2015, grew 7% year over…
Source Analysts seem to be falling over themselves to explain the causes and consequences of the low oil price which is still trading below $60 per barrel as of today. As we are predominantly focusing on the precious metals sector, we are obviously very interested to see what the effect of a lower oil price…
Note from dshort: I’ve updated my periodic look at the Philly Fed ADS Index through yesterday’s release, which included the latest Initial Jobless Claims (for the week ending December 13th). The Philly Fed’s Aruoba-Diebold-Scotti Business Conditions Index (hereafter the ADS index) is a fascinating but relatively little known real-time indicator of business conditions for the…
The fickleness of financial markets is truly amazing at times. Back in May, I suggested that investors were downright sanguine. I even cautioned that the markets may be too calm. But today, things are distinctly different… The price of crude oil has crashed. The Russian ruble is experiencing a proper currency crisis. Emerging markets are getting routed….
RXi Pharmaceuticals (RXII) announced today that is has obtained an exclusive global licensing deal for a phase 2 ready product known as Samcyprone. RXi is licensing the drug from Hapten Pharmaceuticals, LLC. Under the terms of the Agreement RXi will obtain patent rights and assets. In exchange for RXi obtaining Samcyprone the company will be…
RXi Pharmaceuticals (RXII) announced today that is has obtained an exclusive global licensing deal for a phase 2 ready product known as Samcyprone. RXi is licensing the drug from Hapten Pharmaceuticals, LLC. Under the terms of the Agreement RXi will obtain patent rights and assets. In exchange for RXi obtaining Samcyprone the company will be…
The Dow elected only the Daily Bearish on Monday not last Friday which was also a Weekly. Therefore, no Weekly Bearish has been elected leaving 17235 intact. Hence, a closing today above 17,758 today will be an indicator that higher highs are yet to be made. A closing above 17970 will signal a breakout to…
Canadian handset manufacturer BlackBerry Limited (BBRY – Analyst Report), reported third-quarter fiscal 2015 financial results wherein the bottom line outpaced the Zacks Consensus Estimate but the top line missed the same by a huge margin. Third Quarter Results in Detail GAAP loss from continuing operations in the third quarter of fiscal 2015 came in at $148 million or a…
I think this man must be worried. He has a huge weight on his shoulders. This is Thomas Jordan, the head of the Swiss National Bank. Mr. Jordan has excellent academic credentials. He’s a scholar, and a ‘lifer’ at the SNB: University of Berne, PHD Economics Department of Economics at Harvard University,three-year post-doctoral research. 1997…
